Acceleron to Participate in Two Upcoming Healthcare Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences.

Conference Details:

Event: 30th Annual Piper Jaffray Healthcare Conference
Date/Time: Tuesday, November 27, 2018 at 9:00 a.m. EST
Location: New York, NY

Event: 2018 Citi Global Healthcare Conference
Date: Thursday, December 6, 2018
Location: New York, NY

A live webcast of the fireside chat at the Piper Jaffray Conference may be accessed on the Investors/Media page of the Company's website at www.acceleronpharma.com. A replay of each webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181126005149/en/

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
or
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
or
Media:
Matt Fearer, 617-301-9557
Director, Corporate Communications

Source: Acceleron Pharma

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• KBRA Assigns Preliminary Ratings to FMC GMSR Issuer Trust, Series 2026-GT1 (FMC GMSR 2026-GT1)
• Hub Group, Inc. Securities Fraud Class Action Result of Erroneous Financial Statements and Approximately 31% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
• Best Memecoin Trading Platform 2026: MemeToro, Pump.fun, GMGN.AI And AlphaSwap Compared